Lymphoma Clinical Trials in Pennsylvania

Showing 441-460 of 564 trials

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT01471210

The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

Bristol-Myers Squibb124 participantsStarted Feb 2012

Los Angeles, California, United States • Stanford, California, United States • Chicago, Illinois, United States +21 more locations

COMPLETEDPhase 336 miles

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

NCT00053053

RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two nutritional supplements in preventing loss of appetite, weight loss, and fatigue in patients who have stage III or stage IV solid tumors.

CachexiaLymphomaLymphoproliferative Disorder+1 more

Radiation Therapy Oncology Group472 participantsStarted Dec 2002

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +247 more locations

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

Lymphoma Trials in Other Cities

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Cladribine in Patients With Mantle Cell Lymphoma

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

Primary Rituximab and Maintenance

Other Conditions in Pennsylvania